{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:00:10Z","timestamp":1787029210111,"version":"build-2736575974"},"reference-count":48,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The VCOM FY23 Delta Collaborative Research Program","award":["VCOM1038604ULM"],"award-info":[{"award-number":["VCOM1038604ULM"]}]},{"DOI":"10.13039\/100006952","name":"The Louisiana Board of Regents","doi-asserted-by":"publisher","award":["LEQSF-2023-24-ENH-DE-26"],"award-info":[{"award-number":["LEQSF-2023-24-ENH-DE-26"]}],"id":[{"id":"10.13039\/100006952","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pacific Northwest Prostate Cancer SPORE","award":["P50CA97186"],"award-info":[{"award-number":["P50CA97186"]}]},{"name":"PO1 NIH","award":["PO1CA163227"],"award-info":[{"award-number":["PO1CA163227"]}]},{"name":"Institute of Prostate Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background\/Objectives. Prostate cancer (PCa) is among the leading causes of death from cancer in men. Frequent use of androgen receptor inhibitors induces PCa transdifferentiation, leading to poorly differentiated neuroendocrine PCa (NEPC). ROR2 is critical for NEPC pathogenesis by activating ASCL1, promoting lineage plasticity. Protein lysine methylation mediated by N-lysine methyltransferases SMYD2 and its downstream effector EZH2 upregulates the NEPC marker ASCL1 and enhances c-MET signaling, promoting PCa aggression. Epidemiological studies suggest a lower incidence of certain malignancies in Mediterranean populations due to their intake of an olive-phenolics-rich diet. Methods. Cell viability, gene knockdown, and immunoblotting were used for in vitro analyses. A nude mouse NEPC xenograft model evaluated the anti-tumor efficacy of purified and crude oleocanthal. Xenograft tumors were subjected to RNA-seq, qPCR, and Western blot analyses, with clinical validation performed using tissue microarrays. Results. A tissue microarray analysis showed that SMYD2 expression was significantly elevated in PCa tissues with higher IHS versus normal prostate tissue cores. The olive phenolic S\u2013(\u2013)\u2013oleocanthal (OC) suppressed the de novo NEPC NCI-H660 cells proliferation. Male athymic nude mice xenografted with the NCI-H660-Luc cells were used to assess OC effects on de novo NEPC progression and recurrence. Male NSG mice transplanted with LuCaP 93 PDX tumor tissues generated a heterogeneous in vivo model used to assess OC effects against t-NEPC progression. Daily oral 10 mg\/kg OC administration significantly suppressed the NCI-H660-Luc tumor progression and locoregional recurrence after primary tumor surgical excision. OC treatments effectively suppressed the progression of LuCaP 93 PDX tumors. OC-treated tumors revealed downregulation of ROR2, ASCL1, SMYD2, and EZH2, as well as activated c-MET levels versus the placebo control. RNA sequencing of the collected treated NEPC tumors showed that OC disrupted NEPC splicing, translation, growth factor signaling, and neuronal differentiation. Conclusions. This study\u2019s findings validate OC as a novel lead entity for NEPC management by targeting the ROR2-ASCL1-SMYD2-EZH2-c-MET axis.<\/jats:p>","DOI":"10.3390\/nu17243947","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:42:52Z","timestamp":1765978972000},"page":"3947","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Olive Phenolic S\u2013(\u2013)\u2013Oleocanthal as a Novel Intervention for Neuroendocrine Prostate Cancers: Therapeutic and Molecular Insights"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4223-3432","authenticated-orcid":false,"given":"Md Towhidul Islam","family":"Tarun","sequence":"first","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan Y.","family":"Ebrahim","sequence":"additional","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"},{"name":"Department of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal","family":"Dawud","sequence":"additional","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"},{"name":"Department of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-0348","authenticated-orcid":false,"given":"Zakaria Y. Abd","family":"Elmageed","sequence":"additional","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"},{"name":"Department of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-3807","authenticated-orcid":false,"given":"Eva","family":"Corey","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-4064","authenticated-orcid":false,"given":"Khalid A.","family":"El Sayed","sequence":"additional","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"American Cancer Society (2025, March 09). Key Statistics for Prostate Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","article-title":"Development and prevalence of castration-resistant prostate cancer subtypes","volume":"22","author":"Vellky","year":"2020","journal-title":"Neoplasia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Li, C., Cheng, D., and Li, P. (2025). Androgen receptor dynamics in prostate cancer: From disease progression to treatment resistance. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1542811"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bco2.212","article-title":"Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis","volume":"4","author":"Chen","year":"2023","journal-title":"BJUI Compass"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhu, J., Liang, X., Wu, D., Chen, S., Yang, B., Mao, W., and Shen, D. (2021). Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study. Medicine, 100.","DOI":"10.1097\/MD.0000000000025237"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yamada, Y., and Beltran, H. (2021). Clinical and biological features of neuroendocrine prostate cancer. Curr. Oncol. Rep., 23.","DOI":"10.1007\/s11912-020-01003-9"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clgc.2023.04.008","article-title":"Outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer: A multi-institutional study","volume":"21","author":"Eule","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","article-title":"Ror2 as a therapeutic target in cancer","volume":"150","author":"Debebe","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-24-1388","article-title":"Neuroendocrine differentiation in prostate cancer requires ASCL1","volume":"84","author":"Rodarte","year":"2024","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cbic.201900582","article-title":"Analysis of the substrate specificity of the SMYD2 protein lysine methyltransferase and discovery of novel non-histone substrates","volume":"21","author":"Weirich","year":"2020","journal-title":"Chembiochem"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/carcin\/bgp116","article-title":"Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma","volume":"30","author":"Komatsu","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s12276-024-01326-8","article-title":"SMYD family in cancer: Epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance","volume":"56","author":"Han","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_15","unstructured":"Meng, F., Liu, X., Lin, C., Xu, L., Liu, J., Zhang, P., Zhang, X., Song, J., Yan, Y., and Ren, Z. (2020). SMYD2 suppresses APC2 expression to activate the Wnt\/\u03b2-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer. Am. J. Cancer Res., 10."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, L.X., Zhou, J.X., Calvet, J.P., Godwin, A.K., Jensen, R.A., and Li, X. (2018). Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death Dis., 9.","DOI":"10.1038\/s41419-018-0347-x"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41388-024-02945-1","article-title":"Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide","volume":"43","author":"Li","year":"2024","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.celrep.2019.10.004","article-title":"Regulation of EZH2 by SMYD2-mediated lysine methylation is implicated in tumorigenesis","volume":"29","author":"Zeng","year":"2019","journal-title":"Cell Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kaur, P., Shankar, E., and Gupta, S. (2024). EZH2-mediated development of therapeutic resistance in cancer. Cancer Lett., 586.","DOI":"10.1016\/j.canlet.2024.216706"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/13543784.2011.631523","article-title":"The role of HGF\/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials","volume":"20","author":"Varkaris","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mentella, M.C., Scaldaferri, F., Ricci, C., Gasbarrini, A., and Miggiano, G.A.D. (2019). Cancer and Mediterranean diet: A review. Nutrients, 11.","DOI":"10.3390\/nu11092059"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/ptr.6722","article-title":"Anticancer molecular mechanisms of oleocanthal","volume":"34","author":"Quintero","year":"2020","journal-title":"Phytother. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1055\/s-0030-1270724","article-title":"(\u2013)\u2013Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers","volume":"77","author":"Elnagar","year":"2011","journal-title":"Planta Medica"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Qusa, M.H., Abdelwahed, K.S., Siddique, A.B., and El Sayed, K.A. (2021). Comparative gene signature of (\u2013)\u2013oleocanthal formulation treatments in heterogeneous triple negative breast tumor models: Oncological therapeutic target insights. Nutrients, 13.","DOI":"10.3390\/nu13051706"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Siddique, A.B., Ayoub, N.M., Tajmim, A., Meyer, S.A., Hill, R.A., and El Sayed, K.A. (2019). (\u2013)\u2013Oleocanthal prevents breast cancer locoregional recurrence after primary tumor surgical excision and neoadjuvant targeted therapy in orthotopic nude mouse models. Cancers, 11.","DOI":"10.3390\/cancers11050637"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Siddique, A.B., Ebrahim, H.Y., Tajmim, A., King, J.A., Abdelwahed, K.S., Abd Elmageed, Z.Y., and El Sayed, K.A. (2022). Oleocanthal attenuates metastatic castration-resistant prostate cancer progression and recurrence by targeting SMYD2. Cancers, 14.","DOI":"10.3390\/cancers14143542"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tarun, M.T.I., Elsayed, H.E., Ebrahim, H.Y., and El Sayed, K.A. (2025). The olive oil phenolic S\u2013(\u2013)\u2013oleocanthal suppresses colorectal cancer progression and recurrence by modulating SMYD2-EZH2 and c-MET activation. Nutrients, 17.","DOI":"10.3390\/nu17030397"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Siddique, A.B., Ebrahim, H., Mohyeldin, M., Qusa, M., Batarseh, Y., Fayyad, A., Tajmim, A., Nazzal, S., Kaddoumi, A., and El Sayed, K. (2019). Novel liquid-liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (\u2013)\u2013oleocanthal and its oral anti-breast cancer activity. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214798"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Abdelwahed, K.S., Siddique, A.B., Ebrahim, H.Y., Qusa, M.H., Mudhish, E.A., Rad, A.H., Zerfaoui, M., Abd Elmageed, Z.Y., and El Sayed, K.A. (2023). Pseurotin A validation as a metastatic castration-resistant prostate cancer recurrence-suppressing lead via PCSK9-LDLR axis modulation. Mar. Drugs, 21.","DOI":"10.3390\/md21040215"},{"key":"ref_30","unstructured":"Andrews, S. (2025, March 10). FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online: http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: An efficient general-purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15.","DOI":"10.1186\/s13059-014-0550-8"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","article-title":"Pathway enrichment analysis and visualization of omics data using g: Profiler, GSEA, Cytoscape and EnrichmentMap","volume":"14","author":"Reimand","year":"2019","journal-title":"Nat. Protoc."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., and Zhan, L.I. (2021). clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation, 2.","DOI":"10.1016\/j.xinn.2021.100141"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L.D.A., Fran\u00e7ois, R., Grolemund, G., Hayes, A., Henry, L., and Hester, J. (2019). Welcome to the Tidyverse. J. Open Source Softw., 4.","DOI":"10.21105\/joss.01686"},{"key":"ref_38","unstructured":"(2025, March 10). Cellosaurus NCI-H660 (CVCL_1576). Available online: https:\/\/www.cellosaurus.org\/CVCL_1576."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/mc.23536","article-title":"Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling","volume":"62","author":"Li","year":"2023","journal-title":"Mol. Carcinog."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1007\/s11033-021-06701-6","article-title":"Novel insights into SMYD2 and SMYD3 inhibitors: From potential anti-tumoural therapy to a variety of new applications","volume":"48","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Venkadakrishnan, V.B., Presser, A.G., Singh, R., Booker, M.A., Traphagen, N.A., Weng, K., Voss, N.C., Mahadevan, N.R., Mizuno, K., and Puca, L. (2024). Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat. Commun., 15.","DOI":"10.1038\/s41467-024-51156-5"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Murai, F., Koinuma, D., Shinozaki-Ushiku, A., Fukayama, M., Miyaozono, K., and Ehata, S. (2015). EZH2 promotes progression of small cell lung cancer by suppressing the TGF-\u03b2-Smad-ASCL1 pathway. Cell Discov., 1.","DOI":"10.1038\/celldisc.2015.26"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rao, R.A., Dhele, N., Cheemadan, S., Ketkar, A., Jayandharan, G.R., Palakodeti, D., and Rampalli, S. (2015). Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming. Sci. Rep., 5.","DOI":"10.1038\/srep08229"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/mc.23878","article-title":"HGF\/c-Met promotes breast cancer tamoxifen resistance through the EZH2\/HOTAIR-miR-141\/200a feedback signaling pathway","volume":"64","author":"Lai","year":"2025","journal-title":"Mol. Carcinog."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2020.09.003","article-title":"Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"495","author":"Quan","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nair, A.B., and Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm., 7.","DOI":"10.4103\/0976-0105.177703"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Siddique, A.B., King, J.A., Meyer, S.A., Abdelwahed, K., Busnena, B., and El Sayed, K. (2020). Safety evaluations of single dose of the olive secoiridoid S\u2013(\u2013)\u2013oleocanthal in Swiss albino mice. Nutrients, 12.","DOI":"10.3390\/nu12020314"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yang, E., Al-Ghraiybah, N.F., Alkhalifa, A.E., Woodie, L.N., Swinford, S.P., King, J., Greene, M.W., and Kaddoumi, A. (2025). Dose-dependent evaluation of chronic oleocanthal on metabolic phenotypes and organ toxicity in 5xFAD mice. Pharmacol. Res. Nat. Prod., 8.","DOI":"10.1016\/j.prenap.2025.100357"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/24\/3947\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:52:01Z","timestamp":1766065921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/24\/3947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":48,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["nu17243947"],"URL":"https:\/\/doi.org\/10.3390\/nu17243947","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}